Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model

BACKGROUND: Tedizolid is an oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by 10% compared to post- dialysis concentrations....

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Satoshi, Yoshikawa, Shinichi, Sato, Akira, Matsumoto, Tsukasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644586/
https://www.ncbi.nlm.nih.gov/pubmed/37957772
http://dx.doi.org/10.1186/s40780-023-00307-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644586/
https://www.ncbi.nlm.nih.gov/pubmed/37957772
http://dx.doi.org/10.1186/s40780-023-00307-9

Ejemplares similares